EMKT yields 7.76% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 10
Combined, EMKT + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EMKT + PFE for your $10,000?
EMKT focuses on equity securities of companies whose principal business activities are in emerging market countries, as defined by the MSCI Emerging Markets universe. The fund invests mainly in common stocks, but may also hold preferred and convertible securities, including depositary receipts. The strategy emphasizes identifying companies that appear undervalued relative to their earnings, cash flows, or asset values. While the fund can invest across market capitalizations, implementation may from time to time lead to greater exposure to larger companies depending on market conditions. The portfolio may also experience periods of higher weighting in particular sectors or regions as a result of bottom-up stock selection rather than top-down allocation. Under normal conditions, at least 80% of net assets are invested in securities tied to emerging markets. EMKT converted from the Lazard Emerging Markets Core Equity portfolio with $ 123.8 million in assets.
Full EMKT Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.